Changing the course of peripheral arterial disease using adult stem progenitor cells

Mark Niven; Galit Sivak; Shlomo Baytner; Roman Liberson; Shlomo Bulvik; Yael Porat; Michael Frogel; Louis Shenkman; Martin Grajower; Frank Veith; Michael Belkin

doi:10.1007/978-3-030-56954-9_12

Changing the course of peripheral arterial disease using adult stem progenitor cells

Mark Niven, Galit Sivak, Shlomo Baytner, Roman Liberson, Shlomo Bulvik, Yael Porat^*, Michael Frogel, Louis Shenkman, Martin Grajower, Frank Veith, Michael Belkin

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Lower extremity arterial disease affects more than 200 x 10e6 people worldwide causing Critical Limb Ischemia (CLI), also referred to as chronic limb-threatening ischemia (CLTI) a life-threatening disease and the major cause of ischemic amputation. For nonrevascularizable patients, the outlook is bleak and novel therapies are needed. This chapter discusses new approaches including gene therapy and stem/progenitor cell (SPC)-based therapies, including autologous bone marrow-derived cells (BM), MB-mononuclear cells (BM-MNC), mesenchymal stem cells (MSC), mobilized bone marrow cell (PB-MNC), allogeneic cells and ex vivo expanded or activated/differentiated cell products. A preliminary first-in-human trial of a novel treatment is presented that combines immune cell therapy and a stepwise activation and differentiation of SPC. Cells from a standard blood draw (with no pretreatment or mobilization) are transformed, within a day, into a therapeutic product (BGC101) composed of endothelial progenitor cells (EPCs), SPCs, dendritic cells (DCs), and T helper cells. BGC101 was found safe and effective in stabilizing and reversing the course of CLI. Controlled studies on a larger population are planned to evaluate this new concept.

Original language	English
Title of host publication	Stem Cell Therapy for Vascular Diseases
Subtitle of host publication	State of the Evidence and Clinical Applications
Publisher	Springer International Publishing
Pages	245-280
Number of pages	36
ISBN (Electronic)	9783030569549
ISBN (Print)	9783030569532
DOIs	https://doi.org/10.1007/978-3-030-56954-9_12
State	Published - 5 Nov 2020

Keywords

Critical limb ischemia, chronic limb threatening ischemia, diabetes complications
Dendritic cells
Endothelial progenitor cells, bone marrow cells, mesenchymal stem cells
Peripheral artery disease
Regenerative medicine, personalized cell therapies
Stem/progenitor cells therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-030-56954-9_12

Cite this

Niven, M., Sivak, G., Baytner, S., Liberson, R., Bulvik, S., Porat, Y., Frogel, M., Shenkman, L., Grajower, M., Veith, F., & Belkin, M. (2020). Changing the course of peripheral arterial disease using adult stem progenitor cells. In Stem Cell Therapy for Vascular Diseases: State of the Evidence and Clinical Applications (pp. 245-280). Springer International Publishing. https://doi.org/10.1007/978-3-030-56954-9_12

@inbook{0aa3bf9a5d7f49e98de3d3289e484b14,

title = "Changing the course of peripheral arterial disease using adult stem progenitor cells",

abstract = "Lower extremity arterial disease affects more than 200 x 10e6 people worldwide causing Critical Limb Ischemia (CLI), also referred to as chronic limb-threatening ischemia (CLTI) a life-threatening disease and the major cause of ischemic amputation. For nonrevascularizable patients, the outlook is bleak and novel therapies are needed. This chapter discusses new approaches including gene therapy and stem/progenitor cell (SPC)-based therapies, including autologous bone marrow-derived cells (BM), MB-mononuclear cells (BM-MNC), mesenchymal stem cells (MSC), mobilized bone marrow cell (PB-MNC), allogeneic cells and ex vivo expanded or activated/differentiated cell products. A preliminary first-in-human trial of a novel treatment is presented that combines immune cell therapy and a stepwise activation and differentiation of SPC. Cells from a standard blood draw (with no pretreatment or mobilization) are transformed, within a day, into a therapeutic product (BGC101) composed of endothelial progenitor cells (EPCs), SPCs, dendritic cells (DCs), and T helper cells. BGC101 was found safe and effective in stabilizing and reversing the course of CLI. Controlled studies on a larger population are planned to evaluate this new concept.",

keywords = "Critical limb ischemia, chronic limb threatening ischemia, diabetes complications, Dendritic cells, Endothelial progenitor cells, bone marrow cells, mesenchymal stem cells, Peripheral artery disease, Regenerative medicine, personalized cell therapies, Stem/progenitor cells therapy",

author = "Mark Niven and Galit Sivak and Shlomo Baytner and Roman Liberson and Shlomo Bulvik and Yael Porat and Michael Frogel and Louis Shenkman and Martin Grajower and Frank Veith and Michael Belkin",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2020",

month = nov,

day = "5",

doi = "10.1007/978-3-030-56954-9_12",

language = "אנגלית",

isbn = "9783030569532",

pages = "245--280",

booktitle = "Stem Cell Therapy for Vascular Diseases",

publisher = "Springer International Publishing",

}

Niven, M, Sivak, G, Baytner, S, Liberson, R, Bulvik, S, Porat, Y, Frogel, M, Shenkman, L, Grajower, M, Veith, F & Belkin, M 2020, Changing the course of peripheral arterial disease using adult stem progenitor cells. in Stem Cell Therapy for Vascular Diseases: State of the Evidence and Clinical Applications. Springer International Publishing, pp. 245-280. https://doi.org/10.1007/978-3-030-56954-9_12

TY - CHAP

T1 - Changing the course of peripheral arterial disease using adult stem progenitor cells

AU - Niven, Mark

AU - Sivak, Galit

AU - Baytner, Shlomo

AU - Liberson, Roman

AU - Bulvik, Shlomo

AU - Porat, Yael

AU - Frogel, Michael

AU - Shenkman, Louis

AU - Grajower, Martin

AU - Veith, Frank

AU - Belkin, Michael

PY - 2020/11/5

Y1 - 2020/11/5

N2 - Lower extremity arterial disease affects more than 200 x 10e6 people worldwide causing Critical Limb Ischemia (CLI), also referred to as chronic limb-threatening ischemia (CLTI) a life-threatening disease and the major cause of ischemic amputation. For nonrevascularizable patients, the outlook is bleak and novel therapies are needed. This chapter discusses new approaches including gene therapy and stem/progenitor cell (SPC)-based therapies, including autologous bone marrow-derived cells (BM), MB-mononuclear cells (BM-MNC), mesenchymal stem cells (MSC), mobilized bone marrow cell (PB-MNC), allogeneic cells and ex vivo expanded or activated/differentiated cell products. A preliminary first-in-human trial of a novel treatment is presented that combines immune cell therapy and a stepwise activation and differentiation of SPC. Cells from a standard blood draw (with no pretreatment or mobilization) are transformed, within a day, into a therapeutic product (BGC101) composed of endothelial progenitor cells (EPCs), SPCs, dendritic cells (DCs), and T helper cells. BGC101 was found safe and effective in stabilizing and reversing the course of CLI. Controlled studies on a larger population are planned to evaluate this new concept.

AB - Lower extremity arterial disease affects more than 200 x 10e6 people worldwide causing Critical Limb Ischemia (CLI), also referred to as chronic limb-threatening ischemia (CLTI) a life-threatening disease and the major cause of ischemic amputation. For nonrevascularizable patients, the outlook is bleak and novel therapies are needed. This chapter discusses new approaches including gene therapy and stem/progenitor cell (SPC)-based therapies, including autologous bone marrow-derived cells (BM), MB-mononuclear cells (BM-MNC), mesenchymal stem cells (MSC), mobilized bone marrow cell (PB-MNC), allogeneic cells and ex vivo expanded or activated/differentiated cell products. A preliminary first-in-human trial of a novel treatment is presented that combines immune cell therapy and a stepwise activation and differentiation of SPC. Cells from a standard blood draw (with no pretreatment or mobilization) are transformed, within a day, into a therapeutic product (BGC101) composed of endothelial progenitor cells (EPCs), SPCs, dendritic cells (DCs), and T helper cells. BGC101 was found safe and effective in stabilizing and reversing the course of CLI. Controlled studies on a larger population are planned to evaluate this new concept.

KW - Critical limb ischemia, chronic limb threatening ischemia, diabetes complications

KW - Dendritic cells

KW - Endothelial progenitor cells, bone marrow cells, mesenchymal stem cells

KW - Peripheral artery disease

KW - Regenerative medicine, personalized cell therapies

KW - Stem/progenitor cells therapy

UR - http://www.scopus.com/inward/record.url?scp=85149191661&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-56954-9_12

DO - 10.1007/978-3-030-56954-9_12

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:85149191661

SN - 9783030569532

SP - 245

EP - 280

BT - Stem Cell Therapy for Vascular Diseases

PB - Springer International Publishing

ER -

Changing the course of peripheral arterial disease using adult stem progenitor cells

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this